IGM Biosciences Appoints Wayne Godfrey, M.D., as Vice President, Clinical Development

Pioneer in Cancer Immunotherapy Research and Clinical Lead for Kite/Gilead ZUMA-5 Program, Dr. Godfrey Joins Chief Medical Officer, Daniel S. Chen, M.D., Ph.D., to Build IGM’s Clinical Development Function

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Wayne Godfrey, M.D. to the newly created position of Vice President, Clinical Development.

Dr. Godfrey will help lead global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies. He joins IGM with more than 25 years of experience in cancer immunology and immunotherapy research and development, most recently with Kite/Gilead, where he led the CAR-T CD19-directed pivotal Phase II study, ZUMA-5.

“Wayne has been a pioneer in the field of immuno-oncology, including leading the team that first identified human OX40 and OX40-Ligand with Dr. Edgar G. Engleman at Stanford, and he played an important role in the identification, culture, and characterization of human T regulatory cells at the University of Minnesota, in collaboration with Dr. Bruce R. Blazar. Wayne was an inventor on some of the seminal patents licensed in these fields, and I am honored to have the opportunity to work directly with him,” said Daniel S. Chen, Chief Medical Officer of IGM Biosciences. Dr. Chen continued, “Wayne’s scientific immuno-oncology and clinical hematology experience, combined with his proven leadership abilities as past Chief Medical Officer at Bavarian-Nordic Immunotherapeutics and Etubics, provides IGM with valuable new expertise and know-how as we build IGM’s clinical development capabilities.”

“Wayne’s experience with CAR-T approaches to lymphoma and diverse approaches to cancer immunotherapy in solid tumors will provide strong support for the development of our industry-leading IgM technology platform,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.

Dr. Godfrey commented: “I’m fascinated by IGM’s innovative and proprietary engineering approach to bispecific antibodies, which offers many new avenues for creating the next generation of therapeutics for immuno-oncology and beyond. The ability to target cancer antigens that elude IgG-based therapeutics and the framework for adding multiple additional binding domains and payloads are very compelling. Importantly, the ability of multivalent IgM antibodies to powerfully stimulate signaling receptors may also enable us to realize the true potential of OX40 and other TNFr family members as immuno-oncology targets. I’m very excited to have the opportunity to study and develop the potential of IGM’s technology in the clinic.”

Dr. Godfrey conducted research and studied clinical immunology at Stanford, and then went on to run his own lab as a faculty member in Hematology, Oncology and Transplantation at the University of Minnesota and developed and patented methods to purify and culture T regulatory cells. His biotech and pharma experience has included work on antigen presenting cell vaccines, TLR agonists, and viral-prime boost vaccines in both research and global clinical development roles. Subsequently, he also served as the medical lead for multiple clinical studies of Idelalisib in lymphoma (Phase 1-4) and contributed to the filing and FDA approval of Zydelig® at Gilead Sciences. After working on CEA and HER2 targeted adenoviral cancer vaccines at Etubics/Nantcell, he most recently was the clinical development lead for anti-CD19 directed CAR-T cell studies in follicular lymphoma at Kite/Gilead.

Dr. Godfrey has co-authored multiple clinical and scientific publications, including “Identification of a human OX40 ligand, a costimulatory of CD4+ T cells with homology to tumor necrosis factor,” and “PI3Kd Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma,” published in The New England Journal of Medicine. He is also an inventor or co-inventor on multiple patents, including “Regulatory T cells (CD4+CD25+) and their use in immunotherapy.” Dr. Godfrey earned an M.D. from Washington University and completed his internal medicine residency and Clinical Immunology, Hematology and Bone Marrow Transplantation Fellowships at Stanford University.

Dr. Chen and Dr. Godfrey will be responsible for global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies. Dr. Chen joined IGM with more than 20 years of experience in cancer immunotherapy research and development, most recently as Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been dedicated since 2010 to creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases. IGM Biosciences is focused on developing and utilizing IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:

Argot Partners
David Pitts

IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors

Dr. Hambleton Brings More Than 25 Years of Industry and Academic Experience

MOUNTAIN VIEW, Calif., Aug. 15, 2018 – IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Julie Hambleton, M.D., to its Board of Directors. Dr. Hambleton has more than 25 years of academic and industry experience, including 15 years as a leader in preclinical and clinical development at Bristol-Myers Squibb, Five Prime Therapeutics, Clovis Oncology and Genentech. Currently Senior Vice President, Chief Medical Officer and Head of Development at IDEAYA Biosciences, Dr. Hambleton has broad experience across all stages of drug development and was a leader in the successful development of Avastin® and Rubraca®.

“Julie has been at the forefront of some of the most significant advances in oncology/immuno-oncology and hematology, serving as a highly respected medical director and clinical development leader for early-stage companies as well as for some of the most recognized biotechnology and pharmaceutical companies involved in cancer research today,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “Her tremendous wealth of experience leading preclinical and clinical operations and strategy, combined with her global regulatory and post-marketing development experience, will be a significant asset, providing IGM with a broad perspective as we advance our pipeline of IgM oncology antibodies into the clinic, and we look forward to her leadership and guidance as a member of our Board of Directors.”

“IGM Biosciences is pioneering an entirely new approach to treating cancer with the development of IgM antibodies that have the potential to significantly expand and advance our current oncology treatment options,” said Dr. Hambleton. “Preclinical observations with IGM’s proprietary IgM antibodies suggest that their novel approach to creating high-avidity IgM antibodies may allow for the successful treatment of a broad range of cancer patients for whom traditional IgG antibodies and other drugs have failed. I have had the privilege to work with some of the industry’s most groundbreaking research and development teams, and I am very excited to be joining IGM as a member of its Board as the company advances its technology toward the clinic.”

Dr. Hambleton currently serves as Senior Vice President, Chief Medical Officer and Head of Development for IDEAYA Biosciences, an oncology-focused biotechnology company. Prior to IDEAYA, Dr. Hambleton was Vice President and Head of U.S. Medical Affairs Research and Development at Bristol-Myers Squibb, where she was responsible for U.S. medical affairs for immuno-oncology/oncology, immunoscience, cardiovascular and virology products, managing a team of 350 employees. At Five Prime Therapeutics, she led preclinical and clinical development, most recently as Executive Vice President and Chief Medical Officer, and she was a member of the IPO and follow-on financing teams. She was also Vice President of Clinical Development at Clovis Oncology. Dr. Hambleton began her career in the biotechnology industry in 2003 at Genentech as Medical Director for the Avastin program. While at Genentech, Dr. Hambleton served in positions of increasing responsibility, overseeing exploratory clinical development for the company’s antiangiogenic pipeline, expansion of Avastin’s clinical program to support approval of Avastin for renal-cell carcinoma and glioblastoma, and she was most recently Group Medical Director of Global Clinical Development, BioOncology, leading the global, cross-functional team responsible for successful clinical trial execution and multiple marketing authorization applications for the Avastin Breast/Ovarian-GYN program.

Dr. Hambleton completed her medical and oncology-hematology training at the University of California, San Francisco, where she then served on faculty until 2003. She received a B.S. from Duke University and an M.D. from Case Western Reserve University School of Medicine, and she is an author or co-author of more than 50 scientific publications.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been dedicated since 2010 to creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases. IGM Biosciences is focused on developing and utilizing IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:
Argot Partners
David Pitts
212-600-1902
igmbiosciences@argotpartners.com